Topical pan-JAK inhibitor achieved efficacy and fast onset in chronic hand eczema

The topical pan-JAK inhibitor delgocitinib showed remarkable efficacy and a fast onset of action in hand eczema, an indication with a high medical need [1]. Hand eczema is characterised by painful, pruritic, non-infectious inflammatory skin changes on the hands and wrist. The disease is considered chronic when it is lasting ≥3 months or relapsing at least twice a year. Current treatment options are limited to emollients, topical corticosteroids, and calcineurin inhibitors. The topical pan-JAK inhibitor delgocitinib prevents inflammation by blocking several cytokine-mediated signalling cascades involved in the pathophysiology of chronic hand eczema. This explains the motivation for the phase 2b, dose-finding study in chronic hand eczema patients assessing the safety and efficacy of this agent. Participants (n=258) were randomised to delgocitinib cream in 4 different doses (i.e. 1 mg/g, 3 mg/g, 8 mg/g, and 20 mg/g) or a vehicle cream. All treatments w...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 October, 202018 December, 2020